Key result
Initial TAVI cases show 0 deaths or disabling strokes despite suboptimal PVL and pacemaker rates.
Why the study?
To evaluate initial outcomes and identify considerations and challenges in preparation for the next 100 TAVI cases.
Does the use of balloon-expandable versus self-expandable transcatheter heart valves affect early clinical outcomes and complication rates in a single-center Japanese TAVI cohort?
Observational (n=100)
No
Does the use of balloon-expandable versus self-expandable transcatheter heart valves affect early clinical outcomes and complication rates in a single-center Japanese TAVI cohort?
Answers are grounded in this paper and cite their sources.
Initial TAVI experience at a single Japanese center demonstrated excellent safety regarding mortality and stroke, but highlighted the need to optimize valve sizing and depth to reduce paravalvular leak and pacemaker implantation rates.
Objective: Our transcatheter aortic valve implantation (TAVI) program commenced with the first case on July 3, 2021, and reached 100 cases by May 27, 2024. Based on these initial outcomes, we discuss considerations and challenges to be addressed in preparation for the next 100 cases.
No takes yet. Share an insight, caveat, or question.
Narayama et al. (2025) conducted an observational in Severe aortic stenosis (n=100). Self-expandable transcatheter heart valves (SE-THV) vs. Balloon-expandable transcatheter heart valves (BE-THV) was evaluated on Freedom from all-cause mortality and freedom from any stroke.
Synapse has enriched 10 related papers. Consider them for comparative context: